- Home
- HCWB vs NRXS Comparison
HCWB vs NRXS Comparison
Compare HCWB & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- NRXS
- Stock Information
- Founded
- HCWB 2018
- NRXS 2011
- Country
- HCWB United States
- NRXS United States
- Employees
- HCWB N/A
- NRXS N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- HCWB Health Care
- NRXS
- Exchange
- HCWB Nasdaq
- NRXS Nasdaq
- Market Cap
- HCWB 10.8M
- NRXS 13.0M
- IPO Year
- HCWB 2021
- NRXS 2023
- Fundamental
- Price
- HCWB $3.45
- NRXS $2.47
- Analyst Decision
- HCWB Strong Buy
- NRXS Strong Buy
- Analyst Count
- HCWB 1
- NRXS 1
- Target Price
- HCWB $35.00
- NRXS $7.00
- AVG Volume (30 Days)
- HCWB 30.0K
- NRXS 54.4K
- Earning Date
- HCWB 08-18-2025
- NRXS 08-12-2025
- Dividend Yield
- HCWB N/A
- NRXS N/A
- EPS Growth
- HCWB N/A
- NRXS N/A
- EPS
- HCWB N/A
- NRXS N/A
- Revenue
- HCWB $832,841.00
- NRXS $3,217,531.00
- Revenue This Year
- HCWB $178.36
- NRXS $73.05
- Revenue Next Year
- HCWB N/A
- NRXS $130.42
- P/E Ratio
- HCWB N/A
- NRXS N/A
- Revenue Growth
- HCWB N/A
- NRXS 41.93
- 52 Week Low
- HCWB $2.77
- NRXS $1.33
- 52 Week High
- HCWB $100.80
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- HCWB 31.06
- NRXS 49.35
- Support Level
- HCWB $2.77
- NRXS $2.25
- Resistance Level
- HCWB $4.65
- NRXS $2.55
- Average True Range (ATR)
- HCWB 0.36
- NRXS 0.13
- MACD
- HCWB -0.09
- NRXS -0.01
- Stochastic Oscillator
- HCWB 36.22
- NRXS 64.62
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).